FULC Fulcrum Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1680581 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,752.0%
TTM net income YoY90.0%
TTM EPS YoY89.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-27.4%
Net margin-12.2%
FCF margin-3.1%
EBITDA margin-25.3%
Returns
ROE-4.1%
ROA-3.8%
ROIC (approx.)-8.8%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets6.8%
Debt / equity0.00x
Current ratio22.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.23x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0 | $80.00M | $2.81M | $6.34M | $19.16M |
| R&D expense | $56.10M | $63.39M | $71.80M | $76.78M | $69.70M |
| SG&A expense | $28.67M | $36.45M | $41.67M | $41.69M | $30.52M |
| Operating income | -$84.77M | -$21.90M | -$110.66M | -$112.56M | -$81.05M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$74.88M | -$9.72M | -$97.33M | -$109.87M | -$80.85M |
| EBITDA | -$83.38M | -$20.30M | -$108.49M | -$110.15M | -$78.54M |
| EPS (basic) | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 |
| EPS (diluted) | -1.18 | -0.16 | -1.59 | -2.44 | -2.29 |
| Weighted avg. shares (diluted) | 63,355 | 61,984 | 61,310 | 44,991 | 35,361 |
| Balance sheet | |||||
| Cash & equivalents | $197.53M | $58.21M | $25.56M | $35.10M | $35.41M |
| Current assets | $357.48M | $249.92M | $242.20M | $207.52M | $226.00M |
| PP&E, net | $2.82M | $3.90M | $5.22M | $6.91M | $7.37M |
| Total assets | $366.28M | $260.72M | $257.69M | $226.69M | $235.00M |
| Current liabilities | $13.05M | $11.04M | $13.68M | $16.73M | $19.20M |
| Total liabilities | $17.28M | $17.68M | $22.50M | $27.74M | $23.46M |
| Shareholders' equity | $349.00M | $243.03M | $235.19M | $198.94M | $211.54M |
| Shares outstanding | 66.58M | 53.97M | 61.92M | 52.10M | 40.63M |
| Cash flow statement | |||||
| Operating cash flow | -$60.06M | -$2.22M | -$90.97M | -$97.05M | -$78.48M |
| Capital expenditure | $314,000 | $278,000 | $508,000 | $1.96M | $1.71M |
| Free cash flow | -$60.38M | -$2.50M | -$91.47M | -$99.01M | -$80.19M |
| Investing cash flow | $30.72M | $32.23M | -$36.69M | $12.41M | -$129.67M |
| Financing cash flow | $168.67M | $2.75M | $118.12M | $84.32M | $186.51M |
| Depreciation & amortization | $1.39M | $1.59M | $2.17M | $2.41M | $2.52M |
| Stock-based compensation | $12.47M | $14.55M | $14.80M | $13.35M | $11.07M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.